modelS01AA18

Diagram of S01AA18

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:PolymyxinB
ATC code:S01AA18
route:intravenous
compartments:2
dosage:1.5mg
volume of distribution:34.3L
clearance:1.95L/h
other parameters in model implementation

Polymyxin B is an antibiotic primarily used to treat severe Gram-negative bacterial infections, including those caused by multidrug-resistant bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. It is typically administered intravenously or topically and is reserved for serious infections due to potential nephrotoxicity and neurotoxicity. Polymyxin B is approved and used in clinical practice, especially for life-threatening infections where alternative treatments are not effective.

Pharmacokinetics

Pharmacokinetic parameters reported for adult critically ill patients treated with IV polymyxin B, based on population pharmacokinetic analysis.

References

  1. Kubin, CJ, et al., & Yin, MT (2018). Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. Antimicrobial agents and chemotherapy 62(3) –. DOI:10.1128/AAC.01493-17 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29311066

  2. Hanafin, PO, et al., & Rao, GG (2023). A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 29(9) 1174–1181. DOI:10.1016/j.cmi.2023.05.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37217076

  3. Wang, PL, et al., & Yang, J (2022). Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. The Journal of antimicrobial chemotherapy 77(11) 3000–3008. DOI:10.1093/jac/dkac265 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35924405

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)